Drug Trial Radar · NCT06866236
Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression
Last checked: Nov 19, 2026Latest source record: Sep 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
3,000
Planned (sponsor's estimate)
Start
Oct 2025
Primary completion
Oct 2026
Study completion Jul 2027
Sponsor
- Lead sponsor
- Ebima Clifford OkundayeIndustry
- Sponsor type
- Industry
- First posted
- Mar 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.
Conditions
- Chronic Kidney Diseases
- Acute Kidney Injury
- Kidney Failure
Interventions
QRX-3Drug
capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in Glomerular filtration rateTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Neukidney Inc
Pasedena, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.